News Center

Discover all of the trending news of the Ipsen Group


124 results

Patient

COSMIC-021 trial

As part of Ipsen’s ongoing commitment to improve outcomes for patients with high unmet medical…

Innovation

Fulfilling our Bold Promise Through External Innovation

Ivana Magovčević-Liebisch Ph.D., J.D. Executive Vice-President, Chief Business Officer It has just been…

Oncology

It’s time to talk about kidney cancer!

World Kidney Cancer Day is on 20 June, an event created by the International Kidney…

Innovation

How Ipsen is making patient-centric innovation a reality

Bartek Bednarz, Ipsen, Senior Vice-President, Oncology Franchise The world of healthcare is changing. Patients are…

Financial information

Ipsen – Investor Day 2019

To register for the webcast, please Click here.

Patient

Standby statement on lanreotide generic

Paris (France), April 29, 2019 - Following information regarding the filing of a generic…

Financial information
Group

Ipsen completes acquisition of Clementia Pharmaceuticals

Today, Ipsen announced the closing of the acquisition of Clementia Pharmaceuticals. A Canadian clinical-stage biotech…

Oncology

Ipsen is present at ESGE Days with an educational symposium ...

ESGE DAYS 2019 is the second edition of a congress dedicated to increasing quality of…

Group

Building the market access ecosystem

At Eyeforpharma 2019, Ipsen’s Senior VP Market Access, Ulf Staginnus is participating in a…

People

Ipsen champions women in leadership and gender equality this...

International Women’s Day is a great opportunity to celebrate our extraordinary female colleagues around the…

Group

Ipsen acquisition of Clementia Pharmaceuticals – Confe...

Ipsen will host a conference call and web conference today to discuss this announcement. Participants…

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved - 2021